EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. ("BVF") comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), Read More...
Laidlaw acts as Sole Placement Agent on the $4,000,000 NLS Pharmaceutics Ltd. Private Placement
Laidlaw is pleased to have acted as the Sole Placement Agent on the $4,000,000 Private Placement for NLS Pharmaceutics. Read Article
Laidlaw acts as Sole Book-Runner on the $5,750,000 Silo Pharma, Inc. Follow-On Offering
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option: Read Article
Laidlaw acts as Sole Book-Runner on the $5,750,000 Silo Pharma, Inc. Follow-On Offering
Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option: Read Article
Laidlaw Capital Markets is pleased to announce the closing of its expanded and oversubscribed $10,000,000 financing for Perfect Moment.
Perfect Moment is a luxury sportswear brand that has become known as an iconic staple in winter wear. The Perfect Moment collections marry the extreme demands of nature with the world of fashion and can Read More...
Stay In Touch